End Cash (Annual)

End Cash: The amount of cash held by the company for the given period.

BioXcel Therapeutics, Inc. (BTAI) had End Cash of $28.76M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$0.64M
Net Income	$-69.90M
Cost of Goods Sold	$0.16M
Gross Profit	$0.48M
Operating Expenses	$51.10M
Operating Income	$-50.46M
Non-Operating Income/Expense	$-19.44M
Pre-Tax Income	$-69.90M
Normalized Pre-Tax Income	$-69.90M
Income after Taxes	$-69.90M
Income from Continuous Operations	$-69.90M
Consolidated Net Income/Loss	$-69.90M
Normalized Income after Taxes	$-69.90M
EBIT	$-50.46M
EBITDA	$-50.16M
Weighted-Average Shares Outstanding (Basic)	12.21M
Weighted-Average Shares Outstanding (Diluted)	12.21M
Earnings per Share (EPS) (Basic)	$-5.73
Earnings per Share (EPS) (Diluted)	$-5.73
Balance Sheet Financials
Current Assets	$44.69M
Property, Plant, and Equipment	$0.17M
Long-Term Assets	$0.23M
Total Assets	$44.92M
Current Liabilities	$53.93M
Long-Term Debt	$84.66M
Long-Term Liabilities	$86.45M
Total Liabilities	$140.38M
Common Equity	$-95.46M
Tangible Shareholders Equity	$-95.46M
Shareholders Equity	$-95.46M
Common Shares Outstanding	22.33M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-57.62M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$56.52M
Beginning Cash	$29.85M
End Cash	$28.76M
Increase/Decrease in Cash	$-1.10M
Stock-Based Compensation	$2.77M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.83
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-7.84
Debt to Equity Ratio	-1.15
Gross Margin	74.45%
Operating Margin	-7859.97%
EBIT Margin	-7859.97%
EBITDA Margin	-7813.24%
Pre-Tax Profit Margin	-10887.38%
Profit Margin	-10887.38%
Free Cash Flow	$-57.62M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.01
Inventory Turnover	0.23
Receiveable Turnover	2.76
Days Sales in Receivables	132.47
Return on Equity	73.22%
Return on Tangible Equity	73.22%
Return on Assets	-155.62%
Return on Investments	647.19%
Book Value Per Share	$-4.28
Free Cash Flow per Share	$-4.72
Operating Cash Flow per Share	$-4.72

Data from Zacks Investment Research, Inc.